Key statistics
As of last trade BridgeBio Pharma Inc (2CL:STU) traded at 57.32, -16.54% below its 52-week high of 68.68, set on Jan 22, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 53.28 |
|---|---|
| High | 58.88 |
| Low | 53.24 |
| Bid | 57.50 |
| Offer | 57.74 |
| Previous close | 54.06 |
| Average volume | 244.29 |
|---|---|
| Shares outstanding | 192.71m |
| Free float | 170.38m |
| P/E (TTM) | -- |
| Market cap | 13.11bn USD |
| EPS (TTM) | -4.19 USD |
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Announcements
- CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
- BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
- BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
- BridgeBio to Participate in the J.P. Morgan Healthcare Conference
- BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio to Participate in December Investor Conferences
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
More ▼
